P/E Ratio

The green builder secured its Nasdaq status, but a sharp stock drop reveals market skepticism. Can its $78.5M pipeline convince cautious investors?

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Manhattan's top landlord promotes Harrison Sitomer from intern to President, signaling a focus on stability as it navigates a complex office market.

As Prime Drink Group faces heavy losses, the appointment of water industry expert Germain Turpin as interim CEO signals a strategic pivot to its core assets.

Following a historic $2B revenue year, Tradeweb's CEO will address institutional investors, focusing on AI, digital assets, and global market expansion.

The waste giant is renewing its massive share repurchase program and adding a special tool to help its biggest institutional investors cash out.

Treace Medical reports a Q4 revenue dip despite surgeon growth, revealing a strategic shift to lower-priced kits and a challenging 2026 outlook.

A private market index tracking tech giants like SpaceX surged nearly 200% in 14 months, raising questions about a new, exclusive tier of wealth creation.

The Raine Group hires Credit Suisse veteran Anthony Kontoleon, signaling a major push to dominate TMT advisory ahead of an anticipated tech boom.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

With overwhelming bondholder support, the media giant gains financial flexibility for shareholder returns while tightening protections for its creditors.

The French banking giant finalizes a major capital reduction and progresses on a new buyback, signaling strong confidence and rewarding investors.

Toymaker JAKKS Pacific launches an ambitious new platform targeting the multi-billion dollar anime, manga, and creator markets. Can it beat the competition?

Upwork announces a new $300M share buyback, signaling deep confidence in its AI strategy and financial health as it aims to redefine the future of work.

With strong growth and a high valuation, BrightSpring's upcoming Investor Day is a key moment to outline its strategy for profitability and market leadership.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

With results expected to beat guidance, all eyes are on Progyny's upcoming earnings as a key indicator for the rapidly expanding corporate family-building industry.

Align Partners launches a major governance overhaul campaign at Dentium, aiming to fix the 'Korea discount' and unlock value at the undervalued market leader.

Networking giant Belden reports record 2025 revenue and profit while launching a major strategic overhaul to dominate the converging IT and OT markets.

With its IPO complete, Cambridge Acquisition Corp. enters a disciplined SPAC market with a clear focus on wellness, hemp, and psychedelic tech targets.